BeiGene grants RSUs to 147 employees under incentive plan

On November 28, 2025, BeiGene Medicines Ltd. granted 21,274 Restricted Share Units (RSUs) in American Depositary Shares (ADSs) to 147 grantees under its 2016 Share Option and Incentive Plan. These RSUs represent 276,562 underlying shares, accounting for approximately 0.02% of the total issued shares. The closing price of the ADSs on the grant date was $340.61 per ADS.

The vesting schedule for most RSUs involves 25% vesting on each anniversary of the last trading day of the month following the grantee's service start date for the next four years, contingent on continued employment. For two grantees (not senior managers), vesting is 25% on each anniversary of November 28, 2025, for four years. The company confirmed that the grantees are employees of the group and do not fall into categories such as directors, chief executives, or substantial shareholders.

The compensation committee of the board views these RSU grants without performance targets or clawback mechanisms as market competitive and consistent with the company's customary practice. Following these grants, 60,636,094 underlying shares will remain available for future grants under the 2016 Share Option and Incentive Plan.